EKF Diagnostics Holdings plc (AIM: EKF)

Market Cap	129.31M
Revenue (ttm)	52.61M
Net Income (ttm)	2.35M
Shares Out	453.73M
EPS (ttm)	0.01
PE Ratio	55.03
Forward PE	24.55
Dividend	0.01 (4.19%)
Ex-Dividend Date	n/a

Volume	609,468
Open	29.40
Previous Close	28.65
Day's Range	27.60 - 29.40
52-Week Range	23.00 - 34.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 17, 2024

About EKF Diagnostics Holdings

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; Ultracrit, a hematocrit device; DiaSpect Hemoglobin T analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucos...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1990
• Employees: 317
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: EKF